SCHEMBL2024463

SCHEMBL2024463

COC(=O)c1c[nH]c(-c2ccccc2C(F)(F)F)c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 6/20 0.47
CREBBP Q92793 1/20 0.47
MAP2K1 Q02750 1/20 0.44
KDM4E B2RXH2 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CFTR P13569 2/20 0.40
PDK2 Q15119 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
AXL P30530 2/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
TAS2R14 Q9NYV8 1/20 0.39
CYP1A2 P05177 3/20 0.38
CYP3A4 P08684 3/20 0.38
ADORA3 P0DMS8 3/20 0.38
MAPT P10636 3/20 0.38
CYP2C9 P11712 3/20 0.38
CYP2C19 P33261 3/20 0.38
TSHR P16473 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29575721 1.00 NR4A2 (0.47) NR4A2CREBBPMAP2K1KDM4ESMN1; SMN2
SCHEMBL16549389 0.87 KDM4E (0.56) KDM4EPDK2ALDH1A1MAPTTSHR
SCHEMBL3302698 0.85 TAS2R14 (0.47) KDM4EALDH1A1HPGDTAS2R14
SCHEMBL29410865 0.85 TAS2R14 (0.47) KDM4EALDH1A1HPGDTAS2R14
SCHEMBL30889359 0.84 KDM4E (0.45) KDM4EPDK2ALDH1A1CYP1A2CYP2C9
SCHEMBL31407282 0.84 PARP1 (0.46) KDM4ESMN1; SMN2ALDH1A1HPGDTAS2R14
SCHEMBL2359095 0.84 NR4A2 (0.41) NR4A2CREBBPMAP2K1CFTRPDK2
SCHEMBL23275797 0.83 KDM4E (0.44) KDM4ESMN1; SMN2SLC6A3ALDH1A1CYP3A4
SCHEMBL29410845 0.83 KDM4E (0.44) KDM4ESMN1; SMN2SLC6A3ALDH1A1CYP3A4
SCHEMBL2359646 0.83 NR4A2 (0.51) NR4A2MAP2K1SMN1; SMN2CFTRPDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114456098-B Preparation method of medicine Ai Shali ketone for treating diabetic nephropathy 大连理工大学 2024-06-14 CN claimed
CN-114456098-A Preparation method of diabetic nephropathy medicine namely elsamiloride 大连理工大学 2022-05-10 CN claimed
US-20240239746-A1 PREPARATION METHOD FOR PYRROLE AMIDE COMPOUND SUNSHINE LAKE PHARMA CO., LTD. (CN) 2024-07-18 US disclosed
CN-114456098-B Preparation method of medicine Ai Shali ketone for treating diabetic nephropathy 大连理工大学 2024-06-14 CN disclosed
CN-114456098-A Preparation method of diabetic nephropathy medicine namely elsamiloride 大连理工大学 2022-05-10 CN disclosed
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP disclosed
EP-1844020-B1 HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS EXELIXIS INC (US) 2017-09-06 EP disclosed
US-8754118-B2 Atropisomer of pyrrole derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-06-17 US disclosed
US-20140024696-A1 ATROPISOMER OF PYRROLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-01-23 US disclosed
CN-101006052-B Pyrrole derivatives as pharmaceutical agents EXELIXIS INC 2013-11-06 CN disclosed
US-8524918-B2 Atropisomer of pyrrole derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-09-03 US disclosed
US-20100093826-A1 ATROPISOMER OF PYRROLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-04-15 US disclosed
CN-101679243-A atropisomer of pyrrole derivative DAIICHI SANKYO CO 2010-03-24 CN disclosed
EP-2133330-A1 ATROPISOMER OF PYRROLE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2009-12-16 EP disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed
EP-1773768-A4 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2008-08-06 EP disclosed
EP-1844020-A1 HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS Exelixis, Inc. (US) 2007-10-17 EP disclosed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 EP disclosed
WO-2006076202-A1 HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTORS LIGANDS EXELIXIS, INC. (US) 2006-07-20 WO disclosed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 NR4A2 416/4885CREBBP 699/4885MAP2K1 4660/4885
US-20140024696-A1 ATROPISOMER OF PYRROLE DERIVATIVE CYP11B2, CYP11B1, PYCR1 NR4A2 1988/4885CREBBP 3080/4885MAP2K1 4624/4885
US-20100093826-A1 ATROPISOMER OF PYRROLE DERIVATIVE CYP11B2, CYP11B1, PYCR1 NR4A2 1988/4885CREBBP 3080/4885MAP2K1 4624/4885
US-20240239746-A1 PREPARATION METHOD FOR PYRROLE AMIDE COMPOUND HPGDS, HRH4, FAAH NR4A2 3207/4885CREBBP 1819/4885MAP2K1 2846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.